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Abstract
Objectives. Sepsis and acute pancreatitis have similar pathogenetic mechanisms that have been implicated in the progression
of multiple organ failure. Drotrecogin alfa, an analogue of endogenous protein C, reduces mortality in clinical sepsis. Our
objective was to evaluate the early therapeutic effects of activated protein C (APC) in a rat model of acute necrotizing
pancreatitis. Subjects and method. Acute necrotizing pancreatitis was induced by intraductal injection of 5% Na taurocholate.
Hourly bolus injections of saline or recombinant human APC (drotrecogin alfa) was commenced via femoral venous
catheter four hours after the induction of acute pancreatitis. The experiment was terminated nine hours after pancratitis
induction. Animals in group one (n20) had a sham operation while animals in group two (n20) received saline and
animals in group three (n20) received drotrecogin alfa boluses after acute pancreatitis induction. Pancreatic tissue for
histopathologic scores and myeloperoxidase, glutathione reductase, glutathione peroxidase, and catalase activites were
collected, and blood for serum amylase, urea, creatinine, and inleukin-6 measurements was withdrawn. Results. Serum
amylase activity was significantly lower in the APC treated group than the untreated group (17,4359432 U/L vs. 27,4269
118 U/L, respectively). While the serum interleukin-6 concentration in the APC untreated group was significantly lower
than the treated group (9709323 pg/mL vs. 3309368 pg/mL, respectively). Conclusion. In the early phase of acute
pancreatitis, drotrecogin alfa treatment did not result in a significant improvement in oxidative and inflammatory
parameters or renal functions.
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Introduction
Acute pancreatitis includes a spectrum of diseases,
from sterile inflammation at one end, to multisystem
organ failure at the other. In severe acute pancreatitis,
the local pancreatic inflammation extends to a sys-
temic inflammatory response that often leads to
multiple organ failure. It is now clear that certain
cytokines released from inflammatory cells play an
important role in causing the systemic inflammatory
response in acute pancreatitis [1].
A synergy between pro-inflammatory cytokines and
oxidative stress has been reported in the development
of the inflammatory response in acute pancreatitis.
Pro-inflammatory cytokines and oxidative stress in-
duce common signal transduction pathways in the
augmentation of the inflammatory cascade, mainly
through activation of mitogen-activated protein ki-
nases and nuclear factor kappab. Pro-inflammatory
cytokines and oxidative stress contribute to the
formation of a vicious circle in acute pancreatitis [2].
Inflammatory cytokines interact with the microcir-
culation, inducing increased vascular permeability,
thrombosis, and hemorrhage, which results in tissue
necrosis. Activated protein C (APC) inhibits throm-
bin formation, and thus, the clotting cascade; along
with likely inhibiting the inflammatory cascade and
endothelial cell apoptosis [3]. Rabbits with acute
pancreatitis had lower protein C activity than the
sham operated animals [4], and lower plasma levels of
protein C have been measured in non-surviving
patients with acute pancreatitis compared with the
survivors [5].
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Recombinant human APC is indicated in patients
with a high risk of death from sepsis with no absolute
contraindication related to bleeding risk or relative
contraindication that outweights potential benefits
[6]. Severe acute pancreatitis has many similarities
to sepsis syndrome and septic shock [7].
In acute pancreatitis, there may be a place for APC
as the infection dominates the clinical picture in later
stages of the disease. However, in the early stages of
acute pancreatitis, when there is no evidence of
infection, the role of APC is questionable. We aimed
to evaluate the effect of APC in early acute necrotizing
pancreatitis in a sodium taurocholate-induced rat
model in different aspects of acute pancreatitis.
Materials and methods
This randomized controlled experimental study was
carried out in 60 male Wistar albino rats (250300 g)
purchased from Ege University Faculty of Medicine
Research Laboratory. The room was maintained on a
12 hour lightdark cycle and at a temperature of
248C. Food was withdrawn 12 hours before the
experiment.
Experimental model of acute pancreatitis
Acute necrotizing pancreatitis was induced by intra-
ductal infusion of 5% Na taurocholate as described by
Schwarz et al. [8]. Rats were anesthetized by intra-
muscular injection of xylazine (10 mg/kg) plus keta-
mine hydrochloride (50 mg/kg), and smaller doses
were repeated when necessary in order to keep the
rats under anesthesia throughout the experiment. A
midline laparotomy was performed under sterile
conditions. The biliopancreatic duct was cannulated
with a 27-gauge needle. The distal biliopancreatic
duct was ligated to avoid reflux of taurocholate into
the duodenum. To prevent leakage of bile salt into the
liver, the bile duct was clamped temporarily near
the hepatic hilum. Sterile 5% sodium taurocholate
(0.1 mL per 100 g body weight) was infused slowly
under 25 cm H2O pressure.
Venous line
Access to the right femoral vein was accomplished
through an inguinal incision. A 24G cannula was then
inserted into the femoral vein.
Study design
Sixty rats were randomly divided into three groups.
Rats in group 1 (n20) underwent laparotomy and
manipulation of the pancreas (sham procedure), and
intravenous cannula insertion. Four hours post-
abdominal incision, hourly infusion of 0.3 mL saline
was commenced and perpetuated until the termina-
tion of the experiment. Groups 2 and 3 underwent
laparotomy with induction of acute necrotizing pan-
creatitis and intravenous cannula insertion. Rats in
group 2 (positive control; n20) received hourly
boluses of 0.3 mL saline, which were commenced
four hours post-abdominal incision and perpetuated
until the termination of the experiment. Rats in group
3 (treatment group; n20) received 24 mg/kg/h of
recombinant human APC (6 mg in 0.3 mL serum
physiologic/hourly boluses) (Xigris; Lilly, Istanbul,
Turkey). The boluses were commenced four hours
post-acute pancreatitis induction and perpetuated
until the termination of the experiment. The experi-
ments were terminated nine hours after the induction
of acute pancreatitis. Blood samples were taken from
the heart before the animals were sacrificed by
cervical dislocation.
Grading of morphologic severity of acute necrotizing
pancreatitis
Pancreatic tissue was excised and one piece was fixed
in 5% formaldehyde for histologic examination and
another was stored at 708C for myeloperoxidase
(MPO), glutathione reductase, glutathione peroxidase
and catalase activity measurements. Histologic exam-
ination was done under light microscopy after staining
with hematoxylin and eosin by an experienced pathol-
ogist. The severity of necrotizing pancreatitis was
determined by the scoring system described by
Spormann et al. [9]. This score includes the graded
assessment of pancreatic edema (03), inflammatory
infiltration (03), pancreatic necrosis (0, 3, 5, 7),
pancreatic hemorrhage (0, 3, 5, 7), and extrapancrea-
tic fat necrosis (0, 3, 5, 7) for a maximum possible
score of 27.
The rat serum interleukin-6 immunoassey kit was
purchased from Biosource Europa S.A. Belgium.
Serum urea, creatinine, and amylase kits were pur-
chased from Roche Diagnostics. For MPO determi-
nation, the method of Suzuki et al. was used with a
slight modification [10]. Glutathione reductase, glu-
tathione peroxidase, and catalase activities were
determined according to the methods described by
Beutler [11], Paglia [12], and Aebi [13], respectively.
Protein determinations were performed by the
method described by Lowry et al. [14]
All experiments were conducted with approval of
the Animal Research Committee at Ege University
Medical Center, Izmir, Turkey.
Statistics
The results were given as mean9SD. The SPSS
statistical package (SPSS software, PC version
10.01; SPSS, Chicago IL) was used for statistical
analyses. The MannWhitney U and Kruskal Wallis
tests were used when appropriate. PB0.05 was
considered statistically significant.
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Results
Rats with acute necrotizing pancreatitis (ANP) had
extensive parenchyma and fat necrosis, and edema
on histologic examination. The mean histopathologic
scores were 9.192.1 and 9.992.3 in the treatment
group and in the untreated group, respectively. The
difference between the histopathologic scores of the
two groups was not statistically significant.
Mean pancreatic MPO activity was 191692672
U/g of wet weight tissue in the treatment group and
181491900 U/g of wet weight tissue in the untreated
group. The difference between the pancreatic MPO
activities of the two groups was not statistically
significant. The mean pancreatic MPO activity in
the sham group was 189.9967.5 U/g of wet weight
tissue.
The mean serum interleukin-6 concentration
of the APC treated group (9709323 pg/mL) was
significantly higher than the untreated group (3309
368 pg/mL). The mean serum interleukin-6 concen-
tration in the sham group was 7897 pg/mL
(pB0.001) (Figure 1).
Mean serum amylase activity of the treatment
group was significantly lower (17,43594326 U/L)
than that of the APC untreated group (27,4269
11,864 U/L), which is shown in Figure 2 (p0.02).
The mean values of the other parameters are shown
in Table I.
Discussion
Our results show that APC decreases amylase levels
and increases serum IL-6 concentrations in acute
pancreatitis in rats. However, no amelioration in
pancreas histology, pancreas MPO level, pancreas
oxidative stress, or renal functions was achieved.
Acute pancreatitis is similar to severe septic re-
sponses in many aspects. The hemodynamic features
of cardiovascular instability are indistinguishable in
each of these conditions. In addition, there are many
striking similarities in the cytokine and inflammatory
mediator profile, suggesting that the hemodynamic
abnormalities may result from the same pathogenetic
mechanism, albeit as a result of different inflamma-
tory stimuli. Although septic complications of severe
acute pancreatitis do arise, these are usually late
features, and in the early phase of a severe attack,
sterile pancreatic necrosis is found. Evidence suggests
that the important cytokines in the development of
complications and multiple organ failure in severe
acute pancreatitis are tumor necrosis factor alfa,
interleukin-1, interleukin-6, and interleukin-8 [7].
It has been shown that acinar cells produce large
amounts of reactive oxygen species (ROS) during the
early stages of acute pancreatitis in rats [15]. Under
normal conditions, a natural system of scavengers and
antioxidants counteracts the cytotoxicity of ROS
produced from molecular oxygen in the mitochondria
[16]. The reductions in antioxidant levels are con-
cominant with overt signs of pancreatitis, such as
increases in amylase levels and pancreatic edema [17].
The antioxidant enzyme levels represent the severity
in the early phase of acute pancreatitis, and in our
study, the decreases in the antioxidant levels did not
show any difference between the treated and un-
treated groups. In other words, drotrecogin alfa
showed no effect on oxidative stress in the early phase
of acute pancreatitis.
APC has anti-inflammatory properties related, in
part, to inhibition of the production of monocyte
tumour necrosis factor alfa and the modulation of
E-selectin expression by endothelial cells [18]. How-
ever, pancreas MPO activity did not show any































Figure 1. Mean serum interleukin-6 concentrations in APC treated























Figure 2. Mean serum amylase activity in APC treated and
untreated rats with acute pancreatitis.
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In addition, inflammatory infiltrate in pancreas his-
tology and the overall histology scores of both groups
were not statistically different.
During the first 24 hours of acute pancreatitis, IL-6
has 70% sensitivity in predicting the disease severity,
which is higher than C-reactive protein. In acute
pancreatitis and sepsis, higher IL-6 concentrations
correlate with poor outcomes [19]. In this study,
rats in the untreated group had lower IL-6 concentra-
tions than the drotrecogin treated group, which may
indicate that drotrecogin might indeed be deleterious
in the early phase of acute pancreatitis. However,
Li et al. [20] showed that on human umblical vein
endothelial cells stimulated with lipopolysaccharide,
APC increased interleukin-6 levels. Therefore, the
higher interleukin-6 levels in the APC group in our
study may be the direct result of APC administration.
The only parameter improved with APC treatment
was serum amylase, but serum amylase levels do not
have prognostic significance or indicate the severity of
the disease in the rat model or in human acute
pancreatitisis.
With this model of acute pancreatitis combined
with continuous ketamine anesthesia, a high rate of
mortality after the ninth hour of the experiment was
experienced in our preliminary studies. Thus, we
terminated the experiment nine hours post-induction
of ANP.
The search for treatment options for acute pancra-
titis led to many experimental drug studies with
positive results, but none of the molecules or drugs
have come into clinical use. Yamanel et al. reported
that APC improved the pancreas histology, super-
infection rates, and serum markers of inflammation in
the taurocholate acute necrotizing pancreatitis model
[21]. In a similar model, Chen et al. showed that APC
ameliorated acute pancreatitis via regulation of mito-
gen-activated protein kinases [22]. However, in both
studies, a single injection of APC was performed.
According to the provided human data, more than
70% of the administered APC is eliminated within
30 minutes of administration and it is recommended
to be given as a continuous intravenous infusion [23].
We tried to imitate the human use of APC in sepsis, in
dose and route of administration, because there is no
other reasonable reference for APC administration in
a rat model. Even the use of APC in severe sepsis is
questionable because there is a recently published
metaanalysis of clinical trials that does not support the
use of APC in severe sepsis [24].
In conclusion, despite the benefits reported by
others, our results do not provide experimental
evidence to promote APC use in early phase of ANP.
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